skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Anticancer therapy

Abstract

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

Inventors:
Issue Date:
Research Org.:
STC.UNM, Albuquerque, NM (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1496591
Patent Number(s):
10,172,967
Application Number:
15/427,355
Assignee:
STC.UNM (Albuquerque, NM)
DOE Contract Number:  
FG01-001NE23554
Resource Type:
Patent
Resource Relation:
Patent File Date: 2017 Feb 08
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES

Citation Formats

Norenberg, Jeffrey P. Anticancer therapy. United States: N. p., 2019. Web.
Norenberg, Jeffrey P. Anticancer therapy. United States.
Norenberg, Jeffrey P. Tue . "Anticancer therapy". United States. https://www.osti.gov/servlets/purl/1496591.
@article{osti_1496591,
title = {Anticancer therapy},
author = {Norenberg, Jeffrey P.},
abstractNote = {A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2019},
month = {1}
}

Patent:

Save / Share:

Works referenced in this record:

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
journal, September 1982


Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
journal, January 1973


Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
journal, March 1986

  • Cai, R. Z.; Szoke, B.; Lu, R.
  • Proceedings of the National Academy of Sciences, Vol. 83, Issue 6
  • DOI: 10.1073/pnas.83.6.1896

A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides
journal, April 1993


Clinical results of long‐term slow‐release lanreotide treatment of acromegaly
journal, April 1997


RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors
journal, October 2000

  • Halmos, Gabor; Sun, Baodong; Schally, Andrew V.
  • The Journal of Clinical Endocrinology & Metabolism, Vol. 85, Issue 10
  • DOI: 10.1210/jcem.85.10.3509

Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
journal, September 2000


Internalization of [DOTAo,125I-Tyr3]Octreotide by Somatostatin Receptor-Positive Cells In Vitro and In Vivo: Implications for Somatostatin Receptor-Targeted Radio-guided Surgery
journal, January 1999

  • Hof land, Leo J.; Breeman, Wout A. P.; Krenning, Eric P.
  • Proceedings of the Association of American Physicians, Vol. 111, Issue 1
  • DOI: 10.1046/j.1525-1381.1999.09110.x

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
journal, December 2005

  • Kaltsas, G. A.; Papadogias, D.; Makras, P.
  • Endocrine-Related Cancer, Vol. 12, Issue 4
  • DOI: 10.1677/erc.1.01116

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
journal, August 1993

  • Krenning, E. P.; Kwekkeboom, D. J.; Bakker, W. H.
  • European Journal of Nuclear Medicine, Vol. 20, Issue 8
  • DOI: 10.1007/BF00181765

Octreotide
journal, January 1996

  • Lamberts, Steven W. J.; van der Lely, Aart-Jan; de Herder, Wouter W.
  • New England Journal of Medicine, Vol. 334, Issue 4
  • DOI: 10.1056/NEJM199601253340408

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
journal, February 1998

  • Nagy, A.; Schally, A. V.; Halmos, G.
  • Proceedings of the National Academy of Sciences, Vol. 95, Issue 4
  • DOI: 10.1073/pnas.95.4.1794

Combined Modality Therapy of Gemcitabine and Radiation
journal, January 2005


Somatostatin and Its Receptor Family
journal, July 1999


Biochemical and Functional Properties of Somatostatin Receptors
journal, June 1992


A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors
journal, December 2002

  • Reubi, Jean Claude; Eisenwiener, Klaus-Peter; Rink, Hans
  • European Journal of Pharmacology, Vol. 456, Issue 1-3
  • DOI: 10.1016/S0014-2999(02)02651-1

In vitro detection of somatostatin receptors in human tumors
journal, September 1992


Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer
journal, January 1993

  • Stiefel, Friedrich; Morant, Rudolf
  • Supportive Care in Cancer, Vol. 1, Issue 1
  • DOI: 10.1007/BF00326640

The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy
journal, January 1997

  • Szekeres, Thomas; Fritzer-Szekeres, Monika; Elford, Howard L.
  • Critical Reviews in Clinical Laboratory Sciences, Vol. 34, Issue 6
  • DOI: 10.3109/10408369709006424

Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
journal, May 1999


A potent cyclic hexapeptide analogue of somatostatin
journal, July 1981

  • Veber, Daniel F.; Freidinger, Roger M.; Perlow, Debra Schwenk
  • Nature, Vol. 292, Issue 5818
  • DOI: 10.1038/292055a0

Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)
journal, January 1998

  • Wermuth, C. G.; Ganellin, C. R.; Lindberg, P.
  • Pure and Applied Chemistry, Vol. 70, Issue 5
  • DOI: 10.1351/pac199870051129

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.
journal, January 1992

  • Yamada, Y.; Post, S. R.; Wang, K.
  • Proceedings of the National Academy of Sciences, Vol. 89, Issue 1
  • DOI: 10.1073/pnas.89.1.251

Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor Subtype
journal, September 1993

  • Yamada, Y.; Kagimoto, S.; Kubota, A.
  • Biochemical and Biophysical Research Communications, Vol. 195, Issue 2
  • DOI: 10.1006/bbrc.1993.2122

Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides
journal, May 2010

  • Melis, M.; Vegt, E.; Konijnenberg, M.
  • Journal of Nuclear Medicine, Vol. 51, Issue 6, p. 973-977
  • DOI: 10.2967/jnumed.109.074310

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009

  • Rolleman, Edgar; Melis, Marleen; Valkema, Roelf
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Issue 5, p. 1018-1031
  • DOI: 10.1007/s00259-009-1282-y

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009

  • de Jong, Marion; Breeman, Wout; Kwekkeboom, Dik
  • Accounts of Chemical Research, Vol. 42, Issue 7, p. 873-880
  • DOI: 10.1021/ar800188e

Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
journal, May 2008

  • Kwekkeboom, Dik J.; de Herder, Wouter W.; Kam, Boen L.
  • Journal of Clinical Oncology, Vol. 26, Issue 13
  • DOI: 10.1200/JCO.2007.15.2553

Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
journal, September 2006

  • Rolleman, Edgar; Krenning, Eric; Bernard, Bert
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 2, p. 219-227
  • DOI: 10.1007/s00259-006-0232-1

Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
journal, April 2005

  • Kwekkeboom, Dik J.; Teunissen, Jaap J.; Bakker, Willem H.
  • Journal of Clinical Oncology, Vol. 23, Issue 12
  • DOI: 10.1200/JCO.2005.08.066

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002

  • de Jong, Marion; Valkema, Roelf; Jamar, Francois
  • Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 133-140
  • DOI: 10.1053/snuc.2002.31027

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
journal, April 2002

  • Valkema, Roelf; de Jong, Marion; Bakker, Willem H.
  • Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 110-122
  • DOI: 10.1053/snuc/2002.31025

Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010

  • Menda, Y.; O'Dorisio, M.; Kao, S.
  • Journal of Nuclear Medicine, Vol. 51, Issue 10, p. 1524-1531
  • DOI: 10.2967/jnumed.110.075226

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
journal, December 2009

  • Sierra, Maribel; Agazzi, Alberto; Bodei, Lisa
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 24, Issue 6, p. 659-665
  • DOI: 10.1089/cbr.2009.0641

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
journal, April 2008

  • Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Issue 10, p. 1847-1856
  • DOI: 10.1007/s00259-008-0778-1

Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
journal, June 2008


Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008

  • Barone, Raffaella; Walrand, Stéphan; Konijnenberg, Mark
  • Nuclear Medicine Communications, Vol. 29, Issue 3, p. 283-290
  • DOI: 10.1097/MNM.0b013e3282f3d03e

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004


Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004

  • Bodei, Lisa; Handkiewicz-Junak, Daria; Grana, Chiara
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 19, Issue 1, p. 65-71
  • DOI: 10.1089/108497804773391694

Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003

  • Bushnell, David; Menda, Yusuf; Madsen, Mark
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 18, Issue 4, p. 581-588
  • DOI: 10.1089/108497803322287664

90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies
journal, January 2002

  • Paganelli, G.; Bodei, L.; Handkiewicz Junak, D.
  • Biopolymers, Vol. 66, Issue 6, p. 393-398
  • DOI: 10.1002/bip.10349

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
journal, July 2001

  • Waldherr, C.; Pless, M.; Maecke, H.
  • Annals of Oncology, Vol. 12, Issue 7, p. 941-945
  • DOI: 10.1023/A:1011160913619

Yttrium-90 DOTATOC: first clinical results
journal, October 1999

  • Otte, A.; Herrmann, R.; Heppeler, A.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 26, Issue 11, p. 1439-1447
  • DOI: 10.1007/s002590050476

A Comparison of High- Versus Low-Linear Energy Transfer Somatostatin Receptor Targeted Radionuclide Therapy In Vitro
journal, February 2005

  • Nayak, Tapan; Norenberg, Jeffrey; Anderson, Tamara
  • Cancer Biotherapy and Radiopharmaceuticals, Vol. 20, Issue 1
  • DOI: 10.1089/cbr.2005.20.52

Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006